2020 NLCRT Annual Meeting
2020 NLCRT Annual Meeting
Date: December 7-8, 2020
NLCRT Theme: Forging the New Frontier of Lung Cancer
Each year, the NLCRT membership, a nationwide coalition of over 140 professional and national societies, cancer centers, government agencies, research groups, advocacy and policy organizations, and corporate associates convenes to work together on our shared goal to create lung cancer survivors.
We thank all of NLCRT organizational members and non-members along with advocates, survivors, and caregivers for attending the 4th Annual Meeting.
Not currently a member? Learn more about NLCRT membership.
See the 2020 Meeting Executive Summary
Featured Speaker
Harry de Koning, MD, PhD
Dept. of Public Health, Erasmus MC University Medical Center Rotterdam, the Netherlands
Henricus J de Koning is currently serving as Deputy Head and Professor of Public Health & Screening Evaluation, Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.
Koning scientific contributions are in the areas of (1) designing, running and evaluating (often large-scale) multidisciplinary population-based randomized controlled screening trials to establish the efficacy of screening, (2) evaluating active (inter-)national screening programs and clinical tests to establish the effectiveness and (3) guiding public health policies on screening and primary prevention using predictions of favourable and unfavourable effects and the cost of interventions, based on micro-simulation modelling of the natural history of the disease, risk-prediction modelling and cost-effectiveness and cost-utility analyses. Our multidisciplinary and international research results in recommendations on whether or not to introduce screening, surveillance or other preventive interventions for specific diseases and on policy decisions to introduce it in specific ways, either at the population level or in (high risk) patients.
Agenda
[vc_tta_tabs]Session Descriptions & Recordings
WELCOME TO THE NLCRT ANNUAL MEETING AND OPENING SESSION
Welcome and Opening Remarks
Ella Kazerooni, MD, MS, NLCRT Chair, University of Michigan10:05am ETPatient Story
Millicent Wilson, American Lung Association
Harry de Koning, MD, PhD, Erasmus Medical Center, Rotterdam, the Netherlands10:50am ET – 1:00pm ET
SESSION TWO: APPRAISING LUNG CANCER ACROSS THE CARE CONTINUUM
Lung Cancer ScreeningModerator: Peter Mazzone, MD, MPH, Cleveland Clinic
- COVID-19: Screening and Lung Nodule Management Guidelines: Peter Mazzone, MD, MPH, Cleveland Clinic
- Department of Veterans Affairs & GO2 Foundation for Lung Cancer Collaboration: Anita McGlothlin, GO2 Foundation for Lung Cancer
- COVID-19: Screening and Lung Nodule Management Guidelines: Peter Mazzone, MD, MPH, Cleveland Clinic
- First Million Screens in the American College of Radiology Lung Cancer Screening Registry: Gerard Silvestri, MD, MS, Medical University of South Carolina
- USPSTF Lung Cancer Screening Guidelines Update: Ella Kazerooni, MD, MS, University of Michigan
Tobacco Treatment
Moderator: Jamie Ostroff, PhD, Memorial Sloan Kettering Cancer Center
- NCI Smoking Cessation at Lung Examination (SCALE) Collaboration: Stephanie Land, PhD, National Cancer Institute
- NCI Cancer Center Cessation Initiative (C3I): Graham Warren, MD, PhD, Medical University of South Carolina
- Surgeon General Report on Smoking Cessation: Brenna VanFrank, MD, MSPH, Centers for Disease Control and Prevention
Moderator: Bruce Johnson, MD, Dana-Farber Cancer Institute
- Enforcing the Need for State-of-the-Art Surgical Interventions: Brendon Stiles, MD, Weill Cornell Medicine
- Stereotactic Radiotherapy Advancements: Anurag Singh, MD, Roswell Park Comprehensive Cancer Center
- Targeted Therapy Advancements: Raymond Osarogiagbon, MBBS, Baptist Cancer Center, Memphis
- COVID-19 in Patients with Lung Cancer: Gregory Riely, MD, PhD, Memorial Sloan Kettering Cancer Center
Moderator: M. Patricia Rivera, MD, University North Carolina at Chapel Hill
- Addressing Disparities in Lung Cancer Screening and Access: Louise Henderson, PhD, University of North Carolina at Chapel Hill
- Fitness, Depression & Survivorship + COVID-19 in Lung Cancer Care: Brett Bade, MD, Yale University
- HEDIS Measure & Telehealth Related to Screening and Access: Ruth Carlos, MD, MS, University of Michigan
- Improving Access to Biomarker Testing: Devon Adams, RN, MPH, ACS CAN
1:25pm ET – 2:15pm ET
SESSION THREE: POSTER SESSION
The poster session features 16 pre-recorded presentations that highlight lung cancer projects across the continuum of care. The moderated Question & Answer session will begin at 2:00pm ET.
Moderator: Jill Feldman, EGFR Resisters2:15pmBreak2:35pm ET – 4:40pm ET
SESSION FOUR: TASK GROUP SHOWCASES
Co-Moderators:
Joelle Fathi, DNP, ARNP, University of Washington
Jamie Studts, PhD, University of Colorado
Chair: Thomas Houston, MD, American Academy of Family Physicians
Vice-Chair: Jan Eberth, PhD, University of South Carolina
Additional Speakers:
Jennifer Lewis, MD, MS, MPH, Vanderbilt University
Efren Flores, MD, Massachusetts General Hospital
Robert Smith, PhD, American Cancer Society
Celeste Worth, MCHES, LuCa National Training Network, University of Louisville
Chair: Robert Volk, PhD, MD Anderson Cancer Center
Vice Chair: Peter Mazzone, MD,MPH Cleveland Clinic
Additional Presenter:
Ronald Myers, DSW, PhD, Thomas Jefferson University
Chair: Charles White, MD, University of Maryland
Vice Chair: Carey Thomson, MD,MPH Mt. Auburn/Beth Israel Lahey Health
Additional Presenters:
Debra Dyer, MD, National Jewish Hospital
Joelle Fathi, DNP, ARNP, University of Washington
Peter Mazzone, MD, MPH, Cleveland Clinic
Chair: Jamie Ostroff, PhD, Memorial Sloan Kettering Cancer Center
Vice Chair: Joelle Fathi,DNP, ARNP, University of Washington4:40pm ET- 4:45pm ETCLOSING REMARKS AND END OF DAY 1
Ella Kazerooni, MD, MS, NLCRT Chair, University of Michigan2:30pm ETSession Descriptions & Recordings10:00am ET – 10:40am ET
WELCOME TO DAY 2 OF THE NLCRT ANNUAL MEETING
Welcome and Opening Remarks
Douglas Wood, MD, NLCRT Vice Chair, University of Washington10:05am ETPatient Story
Gina Kenney, Patient Advocate
National Estimates of Access to and Utilization of Lung Cancer Screening- Using Geospatial Analysis to Evaluate Access to Lung Cancer Screening in the United States: Liora Sahar, PhD, GISP, American Cancer Society
- State Variation in Low-Dose CT Scanning for Lung Cancer Screening in the United States: Stacey Fedewa, PhD, MPH, American Cancer Society
10:45am ET – 1:05 pm ET
SESSION SIX: NLCRT PRIORITY INITIATIVES AND SPECIAL PROJECTS
NLCRT Stigma Initiatives Panel
Optimizing Lung Cancer Biomarkers
NLCRT Highlight: Summits & InitiativesModerator: Gerard Silvestri, MD, MS, Medical University of South Carolina
- NLCRT Strategic Plan: Robert Smith, PhD, NLCRT PI, American Cancer Society
- Eliminating Lung Cancer Stigma: A National Initiative
- Advocate Perspective – Dusty Donaldson, Dusty Joy Foundation, LungCAN
- Summit and Initiative Overview – Lisa Carter-Harris, PhD, APRN, ANP-C, Memorial Sloan Kettering Cancer Center
- Advocate Perspective – Dusty Donaldson, Dusty Joy Foundation, LungCAN
- Stigma Initiative Strategic Plan – Jamie Studts, PhD, University of Colorado
- Optimizing Lung Cancer Biomarkers in Practice: A National Initiative
- Advocate Perspective– Gina Hollenbeck, RN, BSN, ALK Positive
- Summit and Initiative Overview – M. Patricia Rivera, MD, University of North Carolina at Chapel Hill
- Stakeholder Confessions on Barriers to Comprehensive Biomarker Testing – Farhood Farjah, MD, MPH, University of Washington
- Biomarker Initiative Strategic Plan – Bruce Johnson, MD, Dana-Farber Cancer Institute
Moderator: Richard Wender, MD, Penn Medicine
- State Lung Cancer Coalition-Building Guide: Jessica Olson, PhD, Medical College of Wisconsin
- High Quality Lung Cancer Screening and Nodule Surveillance Programs – Modeling for Implementation and Programmatic Expansion: Carey Thomson, MD, MPH, Mt. Auburn/Beth Israel Lahey Health
- Partnership with American Academy of Family Physicians – Shared Decision-Making Tools: Robert Volk, PhD, MD Anderson Cancer Center
- American Cancer Society Regional Cancer Control Update: Letitia Thompson, MPA, American Cancer Society
SESSION SEVEN: ADVOCACY/HEALTH PLAN/INDUSTRY PANEL
Representatives from Industry, Payer, and Advocacy organizations will discuss the challenges they regard as most important to ensure that biomarker testing for patients with advanced NSCLC becomes routine, efficient, and high quality, and ways in which their organizations can contribute to a national collective initiative to advance biomarker testing and ensure patients receive state of the art care.
Moderator: Robert Smith, PhD, American Cancer Society
Speakers:
Jennifer Norton, Amgen
Katy Miller, AstraZeneca
Bryan Loy, MD, MBA, Humana
Jill Feldman, EGFR Resisters
Upal Basu Roy, PhD, MPH, LUNGevity Foundation
2:30pm – 4:35pm ET
SESSION EIGHT: TASK GROUP SHOWCASE
Co-Moderators:
Jane Kim, MD, MPH, Department of Veterans Affairs
Douglas Wood, MD, University of Washington
Chair: Leah Backhus, MD, MPH, Stanford University
Vice Chair: M. Patricia Rivera, MD, University of North Carolina at Chapel Hill
Additional Speaker:
Kim Sandler, MD, Vanderbilt University
Chair: Jessica Olson, PhD, Medical College of Wisconsin
Vice Chair: Timothy Mullett, MD, MBA, University of Kentucky
Additional Speakers:
Katie Bathje, American Cancer Society
Amy Copeland, MPH, Consultant, State-Based Initiatives Task Group
Chair: Daniel Sullivan, MD, Duke University
Vice Chair: Michael McNitt-Gray, PhD, University of California, Los AngelesPolicy Action Task Group
Chair: Ruth Carlos, MD,MS, University of Michigan
Additional Speakers:
Andrea Borondy Kitts, MS, MPH, Rescue Lung Rescue Life
Sarah Downer, JD, Center for Health Law and Policy Innovation, Harvard4:35 pm ET – 4:45 pm ETCLOSING REMARKS AND END OF ANNUAL MEETING
Ella Kazerooni, MD, MS, NLCRT Chair, University of Michigan
Douglas Wood, MD, NLCRT Vice Chair, University of Washington[/vc_tta_tabs]